To give their glaucoma patients the full benefit of treatment advances, clinicians require clear, actionable insights from knowledgeable subspecialists and researchers. Nitric Oxide in Glaucoma: What Clinicians Need to Know distills and organizes findings about the role of Nitric Oxide (NO) in glaucoma and the role of NO donation in glaucoma therapy in order to make them accessible to ophthalmologists and medical optometrists who want to optimize their decision-making in glaucoma.
This series offers four hours of COPE certified continuing education credit. Upon successful completion of the examinations, participants are prompted to print their certificate and are responsible for uploading their credit to ARBO’s OE Tracker system. Note: Participants are responsible for submitting copies for licensing requirements and maintaining copies for their professional records.
- Chairperson/Activity Director: James C. Tsai, MD, MBA
New York Eye and Ear Infirmary of Mount Sinai, USA
- CME Reviewer: Matthew J. Gray, MD
University of Florida, USA
- CE Reviewer: Tony Cavallerano, OD, FAAO
New England College of Optometry, USA
Nitric Oxide in Glaucoma: What Clinicians Need to Know
Introduction: James C. Tsai, MD, MBA
CHAPTER 1: Pathophysiology of Primary Open-angle Glaucoma
Richard K. Lee, MD, PhD
CHAPTER 2: Therapeutic Strategies for Open-angle Glaucoma
Tony Realini, MD, MPH
CHAPTER 3: Nitric Oxide: Historic Perspectives and Recent Developments
Leo Semes, OD, FAAO
CHAPTER 4: Nitric Oxide in Ocular Physiology
W. Daniel Stamer, PhD
CHAPTER 5: Nitric Oxide and Glaucoma
Anne L. Coleman, MD, PhD
- Review theorized mechanisms of optic nerve damage in glaucoma and recent advances in the understanding of the pathophysiology of glaucomatous optic neuropathy.
- Outline aqueous humor dynamics and the control of IOP in healthy and glaucomatous eyes.
- Identify sites of action for available IOP-lowering agents and recognize current deficiencies in medical treatment of glaucoma.
- Summarize the physiologic function of NO in various bodily systems and identify various NO-donating agents across medicine.
- Explain what is known about NO and its function in the eye.
- Describe the mechanism of action and therapeutic benefit of enhancing NO signaling in glaucoma patients.
- Discuss the potential role of emerging NO-donating therapeutics in glaucoma therapy.
COPE: #54547-GL Event: #113946 Expiration: July 28, 2020
View Publication Take CE Quiz
About the Series
Evolving trends in the diagnosis and treatment of glaucoma have opened a new direction in our approach to treatment. One emerging possibility is nitric oxide, a substance generated in human ocular tissue. This informative supplement offered by New England College of Optometry focuses on “Nitric Oxide in Glaucoma”. It describes potential theories of action and presents compelling evidence how the exciting results from groundbreaking, evidence-based studies, may change our entire approach to treat this important disease.
Accreditation Statement: This activity has been planned and implemented through the joint sponsorship of the New England College of Optometry and Candeo Clinical/Science Communications, LLC. The New England College of Optometry is accredited by The Council on Optometric Practitioner Education® (COPE®), created by the Association of Regulatory Boards of Optometry (ARBO) to accredit continuing education on behalf of optometric licensing boards.